Yanfang Zhang, Xi Quan, Guancheng Song, Ying Song, Shifeng Lou, Kang Zhou, Jianchuan Deng. Clinical effects of CD200 on the outcome of acute myeloid leukemia patients with diverse treatments[J]. Blood&Genomics, 2022, 6(2): 133-140. DOI: 10.46701/BG.2021022022018
Citation: Yanfang Zhang, Xi Quan, Guancheng Song, Ying Song, Shifeng Lou, Kang Zhou, Jianchuan Deng. Clinical effects of CD200 on the outcome of acute myeloid leukemia patients with diverse treatments[J]. Blood&Genomics, 2022, 6(2): 133-140. DOI: 10.46701/BG.2021022022018

Clinical effects of CD200 on the outcome of acute myeloid leukemia patients with diverse treatments

  • CD200 has been associated with a poor prognosis in acute myeloid leukemia (AML). However, the outcome for AML remains heterogeneous and relies more heavily on treatment procedures received by patients. This study aimed to evaluate the correlations between CD200 expression and its prognostic significance in AML treated using diverse treatments. 160 AML patients treated using different chemotherapeutic approaches were retrospectively reviewed from 2018 to 2021, and the effects of CD200 expression on disease outcomes were evaluated. CD200 expressed in 100/160 (62.5%) cases, defined as the CD200-positive (CD200+) group, while the remaining cases were identified as the CD200-negative (CD200) group. The CD200+ group had a significantly lower probability of complete remission after the first induction chemotherapy, both in univariate (P=0.002) and multivariate (P=0.023) analyses. In the entire population, CD200 expression exerted no significant effect on disease-free survival (DFS) (P=0.837) nor overall survival (OS) (P=0.155). In the subgroup analysis, CD200 negatively affected OS in patients receiving less-intensive treatments (P=0.005) and those receiving chemotherapy alone (P=0.019). In conclusion, CD200 positive indicates a low remission rate and further reduces long-term survival in patients receiving less-intensive approaches and chemotherapy-alone. Intensive chemotherapy and stem cell transplantation may reduce the adverse effects of CD200 expression on AML patients.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return